Under construction – not a live service
Sign in

NCT05903066Completed

TRansmural hEaliNg Definition in CroHn's Disease (TRENCH 1)

TRansmural hEaliNg Definition in CroHn's Disease - The TRENCH1 Study

Source: ClinicalTrials.gov · Last updated 4 Nov 2026

Next steps

Brief summary (registry, in English)

Multicenter prospective cross-sectional study of CD patients, its aim is the construction of an objective and reproducible system for evaluation of Transmural healing in Crohn's Disease (CD). Primary objective : Objective definition of depth or grade of transmural healing in relation to radiologic signs observed during Magnetic Resonance Enterography (MRE) in CD

Status (registry)
Completed
Study type
Observational
Enrollment
320 (actual)
First submitted
5 Jun 2023
Start date
28 Sept 2023
Primary completion date
19 Sept 2025
Lead sponsor
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
NCT number
NCT05903066

What you commit to

  • Study type: Observational
  • Participants enrolled: 320
  • From 28 Sept 2023 to the primary completion date, 19 Sept 2025
  • 13 sites in 2 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study design.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • MRE images of poor quality, based on previously defined criteria

Other illness

  • Isolated perianal disease without luminal location

Other

  • Pregnancy during the study
  • People unable to give consent (because of their physical or mental state)
  • Absence of written consent
  • Ulcerative colitis or unclassified IBD
  • Specific postsurgical settings: ileoanal anastomosis, ileostomy or colostomy.
  • Less than 3 evaluable ileocolic segments or more than 3 resected ileocolonic segments (not counting ileocecal valve)
  • Severe obstructive symptoms
  • Symptomatic intra-abdominal abscess
  • Contraindication for MRI

Who the study is looking for

  • ≥ 18 years of age
  • Patient diagnosed with CD for more than 6 months with histological confirmation available in his medical record.
  • Indication for MRE based on routine clinical practice validated by the treating physician
  • Any CD treatment will be authorized, such as biologicals (infliximab, adalimumab, vedolizumab, ustekinumab…), or immunomodulators (azathioprine, 6-mercaptopurine, methotrexate…).
  • The subjects sign and date a written, informed consent form and any required privacy authorization prior to the initiation of the study.
  • A subject can be enrolled into the study only if the grade of TH (assessed by the LRP) corresponding to the subject is not already fulfilled.

Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (13)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
CHU de LiègeLiègeBelgiumUnknown status
CHU Amiens-Picardie - Site SudAmiensFranceUnknown status
CHU de Bordeaux - Hopital Haut LevequeBordeauxFranceUnknown status
APHP - Hopital Ambroise PareBoulogne-BillancourtFranceUnknown status
CHU de Clermont-Ferrand - Hôpital d'EstaingClermont-FerrandFranceUnknown status
CHRU de Lille - Hopital Claude HuriezLilleFranceUnknown status
CHU Limoges - DupuytrenLimogesFranceUnknown status
AP-HM Hôpital NordMarseilleFranceUnknown status
CHU de Montpellier Hôpital Saint EloiMontpellierFranceUnknown status
CHU de NantesNantesFranceUnknown status
CHU de Nîmes - HOPITAL CAREMEAUNîmesFranceUnknown status
Hospices Civils de LyonPierre-BéniteFranceUnknown status
CHU Rennes - Hopital PontchaillouRennesFranceUnknown status

Are you the coordinator? Confirm the details

This page is information, not medical advice. Discuss any trial with your doctor.